A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Tilsotolimod (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms ILLUMINATE-301
- Sponsors Idera Pharmaceuticals
- 06 Nov 2019 According to an Idera Pharmaceuticals media release, approximately 90 sites active in 11 countries.As of October 23, 2019, 342 patients enrolled representing 75% enrollment. Targeting completion of enrollment during first half of 2020.
- 11 Sep 2019 This trial has been suspended in Germany, according to European Clinical Trials Database record.
- 27 Aug 2019 Planned number of patients changed from 308 to 454.